Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes

American Journal of Therapeutics

Volumn 15, Issue 4, 2008, Pages 409-416

  Bermúdez, Valmore ^a   Cano, Raquel ^a   Cano, Clímaco ^a   Bermúdez, Fernando ^a   Leal, Elliuz ^a   Acosta, Karen ^a   Mengual, Edgardo ^a   Arraiz, Nailet ^a   Briceño, Carlos ^a   Gómez, Juan ^a   Bustamante, Magaly ^a   Aparicio, Daniel ^a   Cabrera, Mayela ^a   Valdelamar, Lysney ^a   Rodriguez, Moisés ^a   Manuel, Velasco ^b   Hernández, Rafael ^c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Free fatty acids; HOMA; Insulin; Insulin resistance; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCOFAGE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ROSIGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; BODY MASS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC DIET; DIABETIC PATIENT; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; TREATMENT OUTCOME; BIOLOGICAL MODEL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; FOLLOW UP; HEMOSTASIS; METABOLISM; MIDDLE AGED; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEMOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 51649106018     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318160b909     Document Type: Article

References (48)

1. World Health Organization (WHO). Diabetes. September 2006. Available at www.who.int/mediacentre/factsheets/fs312/en/.
2. DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
3. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-652.
4. Harris MI, Flegal KM, Cowie CC. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518-524.
5. Popkin B. Global nutrition dynamics: the world is shifting rapidly toward a diet linked with noncommunicable diseases Am J Clin Nutr. 2006;84:289-298.
6. Pearson ER, Starkey BJ, Powell RJ, et al. Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet. 2003;362:1275-1281.
7. Melloul I, Marshak S, Cerasi E. Regulation of insulin gene transcription. Diabetologia. 2002;45:309-326.
8. Shulman G. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171-176.
9. Kim JK, Kim Y-J, Fillmore JJ, et al. Prevention of fat-induced insulin resistance with Salicylate. J Clin Invest. 2001;108:437-446.
10. Moneva MH, Dagogo-Jack S. Multiple drug targets in the management of type 2 diabetes. Current Drug Targets. 2002;3:203-221.
11. Andersen P, Lund S, Vestergaard H, et al. Expression of the major insulin regulatable glucose transporter (GLUT4) in skeletal muscle of non-insulin-dependent diabetic patients and healthy subjects before and after insulin infusion. J Clin Endoctrinol Metab. 1993;77:27-32.
12. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med. 2004;116:23S-29S.
13. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function. Diabetes Care. 27; 2004:2597-2602.
14. American Association of Clinical Endocrinologists. The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE system of intensive diabetes self-management. 2002 Update. Endocr Pract. 2002;8:40-82.
15. Yki-Jarvinen H. Glucose toxicity. Endocr Rev. 1992;13: 415-431.
16. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS). JAMA. 2005;281:1999-2012.
17. Alvarsson M, Sundkvist G, Lager I, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. Diabetes Care. 2003;26:2231-2237.
18. Brown JP, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
19. Maedler K, Carr R, Bosco D, et al. Sulfonylurea induced β-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501-506.
20. Matthews DR, Cull CA, Stratton IM, et al. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med. 1998;15:297-303.
21. Kahn SE. The importance of β-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab. 2001;86:4047-4058.
22. Khaw K-T, Wareham N, Luben R, et al. Glycosylated hemoglobin, diabetes and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322:15-18.
23. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
24. Stratton IM, Adler AI, Neu HAW, et al, UK Prospective Diabetes Study Group. The association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ. 2000;321:405-411.
25. Maedler K, Spinas G, Lehmann R, et al. Glucose induces β-cell apoptosis via upregulation of the Fas receptor in human islets. Diabetes. 2001;50:1683-1690.
26. Bell DSH. Insulin as initial therapy for type 2 diabetes is not in the patient's best interest. Endocr Pract. 2004;10: 208-212.
27. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27:1028-1032.
28. Hollander, P. Insulin therapy in type 2 diabetes. Curr Opin Endocrinol Diabetes. 2002;9:139-144.
29. Leahy J. What is the role for insulin therapy in type 2 diabetes? Curr Opin Endocrinol Diabetes. 2003;10: 99-103.
30. Meyer CJ, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104:787-797.
31. Matthews DR, Hosker JP, Rudenski AS, et al. Homoeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
32. Kiayias JA, Vlachou ED, Theodosopoulou E, et al. Rosiglitazone in combination with glimepiride plus metformin in type 2 diabetic patients. Diabetes Care. 2002;25:1251-1252.
33. Ovalle F, Bell DSH. Clinical evidence of thiazolidine-dione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:56-59.
34. Bell DSH, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8: 271-275.
35. Balkau B, Bertrais S, Ducimetiere P, et al. Is there a glycemic threshold for mortality risk? Diabetes Care. 1999;22:696-699.
36. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-1431.
37. Winer N, Sowers J. Epidemiology of diabetes. J Clin Pharmacol. 2004;44:397-405.
38. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1772-1773.
39. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 2003;52:102-110.
40. Donath MY, Ehses JA, Maedler K, et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes. 2005;54:S108-S113.
41. Shimabukuro M, Ohneda M, Lee Y, et al. Role of nitric oxide in obesity-induced cell disease. J Clin Invest. 1997; 100:290-295.
42. Peters AL, Davidson MB. Maximal dose glyburide therapy in markedly symptomatic patients with type 2 diabetes: a new use for an old friend. J Clin Endocrinol Metab. 1996;81:2423-2427.
43. Zeender E, Maedler K, Bosco D, et al. Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J Clin Endocrinol Metab. 2005;89:5059-5066.
44. Bermudez PV, Cano PC, Medina RM, et al. Metformin plus low-dose glimepiride significantly improves homeostasis model assessment for insulin resistance (HOMAIR) and β-cell function (HOMA β-cell) without hyperinsulinemia in patients with type 2 diabetes mellitus. AmJTherapeutics. 2007;14:194-202.
45. Lister CA, Moore GBT, Piercy V, et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content [abstract]. Diabetologia. 1999;42:A150.
46. Wajchenberg B. β-Cell failure in diabetes and preservation by clinical treatment. Endocrine Rev. 2007;28:187-218.
47. VACSDM Study Group. Veterans affairs cooperative study on glycemic control and complications in type II diabetes: results of the feasibility trial. Diabetes Care. 1995; 18:1113-1123.
48. Shuldeiner A, Yong R, Gong DW. Resistin, obesity, and insulin resistance: the emerging role of the adipocyte as on endocrine organ. N Engl J Med. 2001;345:1345-1346.